Live biotherapeutics have been used clinically both as defined probiotics and as undefined faecal microbiota transplants. Two new studies illustrate the risks of administering live microorganisms to highly compromised patients. These risks should be considered in the context of the potential therapeutic value of these treatments.

中文翻译：

---

平衡活生物疗法的风险和回报。

活生物疗法已在临床上用作既定的益生菌和不明确的粪便微生物群移植物。两项新的研究表明，向高度脆弱的患者施用活微生物的风险。这些风险应在这些治疗的潜在治疗价值范围内考虑。